SHTDY Stock - Sinopharm Group Co. Ltd.
Unlock GoAI Insights for SHTDY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $584.51B | $596.57B | $552.15B | $521.05B | $456.41B |
| Gross Profit | $44.26B | $48.51B | $47.43B | $44.05B | $40.32B |
| Gross Margin | 7.6% | 8.1% | 8.6% | 8.5% | 8.8% |
| Operating Income | $16.19B | $20.21B | $20.60B | $19.71B | $17.76B |
| Net Income | $7.05B | $9.05B | $8.53B | $7.76B | $7.19B |
| Net Margin | 1.2% | 1.5% | 1.5% | 1.5% | 1.6% |
| EPS | $11.30 | $14.50 | $13.65 | $12.45 | $11.55 |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Visit WebsiteEarnings History & Surprises
SHTDYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 23, 2026 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | — | $0.77 | — | — |
Q2 2025 | Apr 25, 2025 | — | — | — | — |
Q1 2025 | Mar 21, 2025 | — | — | — | — |
Q4 2024 | Oct 25, 2024 | — | — | — | — |
Q3 2024 | Aug 23, 2024 | — | $0.10 | — | — |
Q2 2024 | Apr 26, 2024 | — | $0.06 | — | — |
Q1 2024 | Mar 22, 2024 | — | $0.09 | — | — |
Q4 2023 | Dec 31, 2023 | — | $0.13 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.11 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.07 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.12 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.10 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.11 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.07 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.10 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.11 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.12 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.06 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.10 | — | — |
Latest News
Frequently Asked Questions about SHTDY
What is SHTDY's current stock price?
What is the analyst price target for SHTDY?
What sector is Sinopharm Group Co. Ltd. in?
What is SHTDY's market cap?
Does SHTDY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SHTDY for comparison